+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Forecast 2024-2030- Product Image
Global Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968662
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Melanoma Drug Market size was estimated at USD 5.40 billion in 2023, USD 5.81 billion in 2024, and is expected to grow at a CAGR of 8.32% to reach USD 9.45 billion by 2030.

Melanoma drugs are a class of pharmaceutical agents specifically designed to treat melanoma, a type of skin cancer. These drugs can be categorized into various types, including immunotherapies, targeted therapies, chemotherapy, and oncolytic virus therapy. Increasing prevalence of melanoma globally, driving innovations in therapeutics. In addition, growing government investments in the healthcare sector and the expansion of reimbursement policies drive market growth. However, the high costs associated with drug development and treatment impact the market growth. Stringent regulatory policies and lengthy approval processes create hindrances to ongoing research and development activities. Furthermore, emerging need for targeted therapy owing to reduced side effects and higher efficiency poses significant opportunities for market growth.

Regional Insights

The Americas have a significant market for melanoma drugs due to a higher incidence of skin cancer. Advanced healthcare infrastructure, high awareness regarding melanoma, and reimbursement policies contribute to robust consumer needs. In the United States, the melanoma drug market is driven by innovation in targeted therapies and immunotherapies, supported by the FDA's expedited approvals for promising treatments. Patient assistance programs and insurance coverage often influence customer purchasing behavior. Europe's melanoma drug market is highly regulated, with an emphasis on efficacious and cost-effective treatments. The European Union (EU) countries exhibit high consumer needs due to increasing melanoma cases and the presence of well-established healthcare systems. The adoption of new treatments is influenced by European Medicines Agency (EMA) regulations and HTA (Health Technology Assessment) bodies that assess the value of new medications. European Union initiatives supporting the ongoing research and development activities in melanoma drugs. Middle Eastern countries exhibit growing investment in healthcare and a rising need for innovative treatments. The Asia Pacific region is experiencing a surge in melanoma cases, with countries including China, Japan, and India contributing significantly to rising consumer needs. In APAC, increased investment in healthcare and innovation has begun to reshape the market. Melanoma drug market in APAC benefits from a combination of government initiatives and a strong pipeline of treatments in clinical trials.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Melanoma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Melanoma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int’l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Acral Lentiginous Melanoma
    • Lentigo Maligna Melanoma
    • Nodular Melanoma
    • Superficial Spreading Melanoma
  • Product
    • Adjuvant Therapy
    • Biochemotherapy
    • Chemotherapy Drugs
      • Dacarbazine (DTIC-Dome)
      • Temozolomide (Temodar)
    • Immunotherapy Drugs
      • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
    • Oncolytic Virus Therapy
    • Targeted Therapy Drugs
      • BRAF Inhibitors
      • MEK Inhibitors
  • Distribution Channel
    • Offline
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Melanoma Drug Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Melanoma Drug Market?
  3. What are the technology trends and regulatory frameworks in the Melanoma Drug Market?
  4. What is the market share of the leading vendors in the Melanoma Drug Market?
  5. Which modes and strategic moves are suitable for entering the Melanoma Drug Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Melanoma Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
5.1.1.2. Increase in government expenditures on healthcare
5.1.1.3. Elevated development of biosimilar in oncology arena
5.1.2. Restraints
5.1.2.1. High costs associated with drug development and treatment
5.1.3. Opportunities
5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
5.1.3.2. Ongoing research and development activities to introduce effective drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies and lengthy approval process
5.2. Market Segmentation Analysis
5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Melanoma Drug Market, by Type
6.1. Introduction
6.2. Acral Lentiginous Melanoma
6.3. Lentigo Maligna Melanoma
6.4. Nodular Melanoma
6.5. Superficial Spreading Melanoma
7. Melanoma Drug Market, by Product
7.1. Introduction
7.2. Adjuvant Therapy
7.3. Biochemotherapy
7.4. Chemotherapy Drugs
7.5.1. Dacarbazine (DTIC-Dome)
7.5.2. Temozolomide (Temodar)
7.5. Immunotherapy Drugs
7.6.1. Checkpoint Inhibitors
7.6.2. CTLA-4 Inhibitors
7.6. Oncolytic Virus Therapy
7.7. Targeted Therapy Drugs
7.8.1. BRAF Inhibitors
7.8.2. MEK Inhibitors
8. Melanoma Drug Market, by Distribution Channel
8.1. Introduction
8.2. Offline
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3. Online
9. Americas Melanoma Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Melanoma Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Melanoma Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Sun Pharma and Philogen’s Melanoma Drug Shows Promising Outcome in Phase 3 Trial
12.3.2. New Product Launch & Enhancement
12.3.2.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
12.3.3. Award, Recognition, & Expansion
12.3.3.1. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AB Science
13.1.2. AbbVie Inc.
13.1.3. Amgen Inc.
13.1.4. AstraZeneca PLC
13.1.5. Bristol-Myers Squibb Company
13.1.6. CK Life Sciences Int’l., (Holdings) Inc.
13.1.7. Clinigen Group PLC
13.1.8. Eli Lilly and Company
13.1.9. Enzon Pharmaceuticals, Inc.
13.1.10. F. Hoffmann-La Roche Ltd.
13.1.11. Genentech, Inc.
13.1.12. GlaxoSmithKline PLC
13.1.13. Hikma Pharmaceuticals PLC
13.1.14. Immunocore Limited
13.1.15. Merck KGaA
13.1.16. Moderna, Inc
13.1.17. Novartis AG
13.1.18. Pfizer, Inc.
13.1.19. Philogen S.p.A.
13.1.20. Regeneron Pharmaceuticals Inc.
13.1.21. Sun Pharmaceutical Industries Limited
13.1.22. Taj Pharmaceuticals Limited
13.1.23. Takeda Pharmaceutical Company Limited
13.1.24. Wellona Pharma
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MELANOMA DRUG MARKET DYNAMICS
FIGURE 7. MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 10. MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 11. MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 15. MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 19. MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 24. MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 29. MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 54. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 57. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 58. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 59. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 91. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 93. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 94. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 95. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 96. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 98. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 101. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 102. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 103. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 112. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 116. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 117. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 154. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 157. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 158. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 159. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 176. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 178. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 179. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 180. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 181. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. DENMARK MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 183. EGYPT MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. EGYPT MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. EGYPT MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 186. EGYPT MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 187. EGYPT MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 188. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. EGYPT MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. FINLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. FINLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 199. FRANCE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 200. FRANCE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 201. FRANCE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. FRANCE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. GERMANY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 206. GERMANY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 207. GERMANY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 208. GERMANY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 209. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. GERMANY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 218. ITALY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. ITALY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 221. ITALY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 222. ITALY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 223. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. ITALY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 241. NORWAY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 246. POLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 248. POLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 249. POLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 250. POLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 251. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. POLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 253. QATAR MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 255. QATAR MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 256. QATAR MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 257. QATAR MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 258. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. QATAR MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 282. SPAIN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 283. SPAIN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 284. SPAIN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 285. SPAIN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 286. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. SPAIN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 302. TURKEY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 303. TURKEY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. TURKEY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 305. TURKEY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 306. TURKEY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 307. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. TURKEY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 316. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 318. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 320. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 323. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 324. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 325. MELANOMA DRUG MARKET LICENSE & PRICING

Companies Mentioned

  • AB Science
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CK Life Sciences Int’l., (Holdings) Inc.
  • Clinigen Group PLC
  • Eli Lilly and Company
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Immunocore Limited
  • Merck KGaA
  • Moderna, Inc
  • Novartis AG
  • Pfizer, Inc.
  • Philogen S.p.A.
  • Regeneron Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Wellona Pharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.81 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.45 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Melanoma Drugs Global Market Report 2024 - Product Image

Melanoma Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Melanoma Therapeutics: Global Strategic Business Report - Product Image

Melanoma Therapeutics: Global Strategic Business Report

  • Report
  • 162 Pages
  • Global
From
Melanoma Therapeutics Global Market Report 2024 - Product Image

Melanoma Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Melanoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Melanoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Metastatic Uveal Melanoma (MUM) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Metastatic Uveal Melanoma (MUM) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.